{"mainPropery":{"diseaseId":2562,"diseaseName":"Gray platelet syndrome","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/2562/gray-platelet-syndrome","synonyms":["GPS","Platelet alpha-granule deficiency","Marked decrease or absence of alpha-granules and of platelet-specific alpha-granule proteins"],"synonyms-with-source":[{"name":"GPS"},{"name":"Platelet alpha-granule deficiency"},{"name":"Marked decrease or absence of alpha-granules and of platelet-specific alpha-granule proteins"}],"identifiers":[{"identifierType":"OMIM","identifierId":"139090"},{"identifierType":"ORPHANET","identifierId":"721"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"}],"organizations":[{"resourceID":248,"resourceName":"Platelet Disorder Support Association","abbreviation":"","address1":"8751 Brecksville Road","address2":"Suite 150","address3":"","address4":"","address5":"","city":"Cleveland","state":"OH","zip":"44141","country":"United States","phone":"440-746-9003","tty":"","tollFree":"87-PLATELET (1-877-528-3538)","fax":"844-270-1277","email":"pdsa@pdsa.org","url":"http://www.pdsa.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/139090' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=139090' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Gray platelet syndrome. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Gray+platelet+syndrome%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Gray platelet syndrome. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/gray-platelet-syndrome' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Gray platelet syndrome. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0272302' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=721' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:139090' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":5377,"questionText":"What is gray platelet syndrome (GPS)?","answerText":"<strong>Gray platelet syndrome (GPS)</strong> is a rare inherited bleeding disorder characterized by platelets that have a gray appearance, severe <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\" target=_blank>thrombocytopenia</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm\" target=_blank>myelofibrosis</a>, and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm\" target=_blank>splenomegaly</a>. About 60 cases from various populations around the world have been described in the literature to date. GPS results from&nbsp;the absence or&nbsp;reduction of alpha-granules in platelets, which store&nbsp;proteins that promote platelet adhesiveness and wound healing when secreted during an injury. GPS is caused by <a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/genemutation\" target=_blank>mutations</a> in the <em>NBEAL2</em> gene and inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> manner.[4432][4433]&nbsp;","dateModified":"2011-10-03T11:50:00"},"basicQuestions":[{"questionId":5378,"questionText":"What are the signs and symptoms of gray platelet syndrome (GPS)?","answerText":"Signs and symptoms usually appear at birth or in early childhood and include&nbsp;low platelet counts, easy bruising, prolonged bleeding, and nose bleeds.&nbsp;Affected individuals often have <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm\">myelofibrosis</a>&nbsp;and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm\">splenomegaly</a>. Bleeding tendency is usually mild to moderate in those with mild <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\">thrombocytopenia</a>. However, the&nbsp;thrombocytopenia and myelofibrosis are usually progressive in nature.&nbsp;GPS may result in fatal hemorrhage (bleeding), especially in adulthood when platelet counts are further decreased. Female patients may develop heavy <a href=\"http://www.nlm.nih.gov/medlineplus/menstruation.html\">menstrual bleeding</a>.[4432]","dateModified":"2011-10-03T11:48:00","resourceClassificationName":"Symptoms","references":[{"referenceId":4432,"authors":"Gunay-Aygun M & Gahl WA","articleTitle":"Gray platelet syndrome","bookWebsiteJournalTitle":"Orphanet","date":"June 2011","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=721","dateAccessed":"2011-10-03T00:00:00"}]},{"questionId":5379,"questionText":"How might gray platelet syndrome (GPS) be treated?","answerText":"There is no specific treatment for GPS, but management involves anticipating and preventing risks of bleeding (e.g. possible platelet transfusions before surgery). Treatment may also include administration of <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a608010.html\">desmopressin</a>. <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002944.htm\">Splenectomy</a>&nbsp;should be considered to increase the platelet counts in those whose platelet counts decrease to approximately 30,000/microliter. Prognosis is generally good early in life when <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\">thrombocytopenia</a>&nbsp;is mild. Those&nbsp;with platelets counts less than 30,000/microliter are at risk for life-threatening bleeding.[4432] ","dateModified":"2011-10-03T11:49:00","resourceClassificationName":"Treatment","references":[{"referenceId":4432,"authors":"Gunay-Aygun M & Gahl WA","articleTitle":"Gray platelet syndrome","bookWebsiteJournalTitle":"Orphanet","date":"June 2011","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=721","dateAccessed":"2011-10-03T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":32357,"abbreviatedInquiry":"What is gray platelet syndrome?&nbsp;My daughter has low platelet counts and I am desperate for answers.","caseQuestions":[{"questionId":5377,"questionText":"What is gray platelet syndrome (GPS)?","answerText":"<strong>Gray platelet syndrome (GPS)</strong> is a rare inherited bleeding disorder characterized by platelets that have a gray appearance, severe <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\" target=_blank>thrombocytopenia</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm\" target=_blank>myelofibrosis</a>, and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm\" target=_blank>splenomegaly</a>. About 60 cases from various populations around the world have been described in the literature to date. GPS results from&nbsp;the absence or&nbsp;reduction of alpha-granules in platelets, which store&nbsp;proteins that promote platelet adhesiveness and wound healing when secreted during an injury. GPS is caused by <a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/genemutation\" target=_blank>mutations</a> in the <em>NBEAL2</em> gene and inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> manner.[4432][4433]&nbsp;","dateModified":"2011-10-03T11:50:00","references":[{"referenceId":4432,"authors":"Gunay-Aygun M & Gahl WA","articleTitle":"Gray platelet syndrome","bookWebsiteJournalTitle":"Orphanet","date":"June 2011","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=721","dateAccessed":"2011-10-03T00:00:00"},{"referenceId":4433,"authors":"","articleTitle":"Gray Platelet Syndrome, GPS","bookWebsiteJournalTitle":"Online Mendelian Inheritance of Man (OMIM)","date":"August 2011","url":"http://omim.org/entry/139090","dateAccessed":"2011-10-03T00:00:00"}]},{"questionId":5378,"questionText":"What are the signs and symptoms of gray platelet syndrome (GPS)?","answerText":"Signs and symptoms usually appear at birth or in early childhood and include&nbsp;low platelet counts, easy bruising, prolonged bleeding, and nose bleeds.&nbsp;Affected individuals often have <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm\">myelofibrosis</a>&nbsp;and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm\">splenomegaly</a>. Bleeding tendency is usually mild to moderate in those with mild <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\">thrombocytopenia</a>. However, the&nbsp;thrombocytopenia and myelofibrosis are usually progressive in nature.&nbsp;GPS may result in fatal hemorrhage (bleeding), especially in adulthood when platelet counts are further decreased. Female patients may develop heavy <a href=\"http://www.nlm.nih.gov/medlineplus/menstruation.html\">menstrual bleeding</a>.[4432]","dateModified":"2011-10-03T11:48:00","resourceClassificationName":"Symptoms","references":[{"referenceId":4432,"authors":"Gunay-Aygun M & Gahl WA","articleTitle":"Gray platelet syndrome","bookWebsiteJournalTitle":"Orphanet","date":"June 2011","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=721","dateAccessed":"2011-10-03T00:00:00"}]},{"questionId":5379,"questionText":"How might gray platelet syndrome (GPS) be treated?","answerText":"There is no specific treatment for GPS, but management involves anticipating and preventing risks of bleeding (e.g. possible platelet transfusions before surgery). Treatment may also include administration of <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a608010.html\">desmopressin</a>. <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002944.htm\">Splenectomy</a>&nbsp;should be considered to increase the platelet counts in those whose platelet counts decrease to approximately 30,000/microliter. Prognosis is generally good early in life when <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\">thrombocytopenia</a>&nbsp;is mild. Those&nbsp;with platelets counts less than 30,000/microliter are at risk for life-threatening bleeding.[4432] ","dateModified":"2011-10-03T11:49:00","resourceClassificationName":"Treatment","references":[{"referenceId":4432,"authors":"Gunay-Aygun M & Gahl WA","articleTitle":"Gray platelet syndrome","bookWebsiteJournalTitle":"Orphanet","date":"June 2011","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=721","dateAccessed":"2011-10-03T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":8265,"phenoTypeName":"Bruising susceptibility","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":15512,"phenoTypeName":"Thrombocytopenia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9733,"phenoTypeName":"Abnormality of the menstrual cycle","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5714,"phenoTypeName":"Epistaxis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":7953,"phenoTypeName":"Myelodysplasia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15295,"phenoTypeName":"Abnormal number of alpha granules","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":15614,"phenoTypeName":"Impaired collagen-induced platelet aggregation","percentRanges":"-"},{"phenoTypeId":15390,"phenoTypeName":"Impaired thrombin-induced platelet aggregation","percentRanges":"-"},{"phenoTypeId":10065,"phenoTypeName":"Menorrhagia","percentRanges":"-"},{"phenoTypeId":13245,"phenoTypeName":"Myelofibrosis","percentRanges":"-"},{"phenoTypeId":5255,"phenoTypeName":"Progressive","percentRanges":"-"},{"phenoTypeId":8879,"phenoTypeName":"Prolonged bleeding time","percentRanges":"-"},{"phenoTypeId":4844,"phenoTypeName":"Reduced quantity of Von Willebrand factor","percentRanges":"-"},{"phenoTypeId":15622,"phenoTypeName":"Reduced von Willebrand factor activity","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Gray_platelet_syndrome"}